Payment overview · 2025
General Payments
$750.44
31 reported records · 10 companies
Healthcare provider profile · identity verified
Robert L Elder, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HARTSVILLE, SC · NPI 1154353787
Verified facts
What the public records show
CMS Open Payments records show Robert L Elder, M.D. received $750.44 in general payments during 2025 across 31 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 37.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $281.04 | 37.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $132.70 | 17.7% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $109.18 | 14.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.82 | 9.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.06 | 6.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.23 | 5.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.32 | 3.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.58 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.85 | 2.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.66 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $750.44 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $281.04 | 13 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $109.18 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $100.00 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 160 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
160 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 969 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 781 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 137 |
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 531 | 151 |
| Omeprazole | Omeprazole | 511 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 477 | 139 |
| Gabapentin | Gabapentin | 467 | 130 |
| Furosemide | Furosemide | 409 | 113 |
| Prednisone | Prednisone | 409 | 213 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 398 | 54 |
| Tramadol Hcl | Tramadol Hcl | 357 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 355 | 120 |
| Losartan Potassium | Losartan Potassium | 331 | 101 |
| Potassium Chloride | Potassium Chloride | 311 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 301 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 87 |
| Lisinopril | Lisinopril | 272 | 74 |
| Zolpidem Tartrate | Zolpidem Tartrate | 272 | 40 |
| Trazodone Hcl | Trazodone Hcl | 261 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 248 | 68 |
| Tizanidine Hcl | Tizanidine Hcl | 246 | 98 |
| Metformin Hcl | Metformin Hcl | 237 | 66 |
| Jardiance | Empagliflozin | 223 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 211 | 27 |
| Montelukast Sodium | Montelukast Sodium | 205 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 195 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 81 |
| Carvedilol | Carvedilol | 188 | 58 |
| Donepezil Hcl | Donepezil Hcl | 178 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 71 |
| Eliquis | Apixaban | 168 | 46 |
| Valsartan | Valsartan | 162 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 58 |
| Mounjaro | Tirzepatide | 160 | 24 |
| Sertraline Hcl | Sertraline Hcl | 155 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 152 | 114 |
| Famotidine | Famotidine | 152 | 43 |
| Fluconazole | Fluconazole | 144 | 91 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 133 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 131 | 40 |
| Testosterone Cypionate | Testosterone Cypionate | 128 | 26 |
| Clonazepam | Clonazepam | 125 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 124 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 118 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 36 |
| Memantine Hcl | Memantine Hcl | 115 | 31 |
| Finasteride | Finasteride | 111 | 17 |
| Temazepam | Temazepam | 109 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 31 |
| Meloxicam | Meloxicam | 104 | 40 |
| Allopurinol | Allopurinol | 101 | 33 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 101 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 101 | 48 |
| Ozempic | Semaglutide | 100 | 24 |
| Xarelto | Rivaroxaban | 98 | 19 |
| Azithromycin | Azithromycin | 97 | 69 |
| Bupropion Xl | Bupropion Hcl | 96 | 29 |
| Mirtazapine | Mirtazapine | 96 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 33 |
| Levofloxacin | Levofloxacin | 92 | 64 |
| Metformin Hcl Er | Metformin Hcl | 91 | 30 |
| Sucralfate | Sucralfate | 91 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 91 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 90 | 26 |
| Celecoxib | Celecoxib | 89 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 88 | 73 |
| Entresto | Sacubitril/Valsartan | 86 | 22 |
| Ezetimibe | Ezetimibe | 86 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 19 |
| Pregabalin | Pregabalin | 80 | 16 |
| Lorazepam | Lorazepam | 78 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 39 |
| Simvastatin | Simvastatin | 77 | 25 |
| Dexamethasone | Dexamethasone | 75 | 63 |
| Farxiga | Dapagliflozin Propanediol | 75 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 48 |
| Glimepiride | Glimepiride | 74 | 21 |
| Meclizine Hcl | Meclizine Hcl | 74 | 26 |
| Buspirone Hcl | Buspirone Hcl | 72 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 22 |
| Ibuprofen | Ibuprofen | 65 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 19 |
| Alendronate Sodium | Alendronate Sodium | 61 | 18 |
| Nystatin | Nystatin | 61 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 21 |
| Spironolactone | Spironolactone | 58 | 23 |
| Linzess | Linaclotide | 57 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Levetiracetam | Levetiracetam | 49 | 13 |
| Nifedipine Er | Nifedipine | 49 | 18 |
| Synthroid | Levothyroxine Sodium | 47 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 42 | suppressed |
| Estradiol | Estradiol | 42 | 13 |
| Fenofibrate | Fenofibrate | 41 | 17 |
| Mupirocin | Mupirocin | 41 | 28 |
| Cephalexin | Cephalexin | 38 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 25 |
| Diazepam | Diazepam | 37 | 13 |
| Myrbetriq | Mirabegron | 37 | 12 |
| Atenolol | Atenolol | 36 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Cefdinir | Cefdinir | 32 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 13 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Bumetanide | Bumetanide | 29 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 14 |
| Topiramate | Topiramate | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 14 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 14 | 11 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $750.44 · 31 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | BREZTRI, CAPLYTA, KISUNLA, Kerendia, Korlym, MOUNJARO, OTEZLA, QULIPTA, REPATHA, REXULTI, UBRELVY, VERQUVO, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error